Recent News

• 06.09.2025 - PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025
• 06.09.2025 - PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025
• 06.09.2025 - PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints
• 06.09.2025 - PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints
• 06.06.2025 - PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025
• 06.06.2025 - PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025
• 06.05.2025 - Boobalan Pachaiyappan
• 06.05.2025 - Boobalan Pachaiyappan
• 05.20.2025 - PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025
• 05.20.2025 - PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

Recent Filings

• 06.09.2025 - EX-99.1 EX-99.1
• 06.09.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.30.2025 - EX-99.1 EX-99.1
• 05.30.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.28.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.21.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.21.2025 - EX-99.1 EX-99.1
• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors